Inactive Instrument

Opiant Pharmaceuticals, Inc.

Equities

OPNT

US6837501039

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Indivior completes acquisition of Opiant Pharmaceuticals AN
Indivior Wraps Up Deal to Buy Opiant Pharmaceuticals MT
Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from NASDAQ Composite Index CI
Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from S&P TMI Index CI
Indivior PLC completed the acquisition of Opiant Pharmaceuticals, Inc. from a group of shareholders. CI
Transcript : Opiant Pharmaceuticals, Inc. - Shareholder/Analyst Call
Indivior Wins US Regulatory Nod To Acquire Opiant Pharmaceuticals MT
Indivior announces expiry of waiting period for Opiant purchase AN
Opiant Pharmaceuticals Says Waiting Period Expires for Proposed Takeover by Indivior Expires MT
Indivior Nears Acquisition of Opiant Pharmaceuticals MT
Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals RE
Opiant Pharmaceuticals Granted FDA Priority Review for Opioid Overdose Therapy MT
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose CI
Insider Sell: Opiant Pharmaceuticals MT
Opiant Pharmaceuticals Completes Rolling Submission of New Drug Application for Potential Opioid Overdose Drug MT
Opiant Pharmaceuticals, Inc. Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose CI
Healthcare Shares Climb, Beating Broader Market -- Healthcare Roundup DJ
Top Midday Gainers MT
MarketScreener's World Press Review : November 14, 2022 Our Logo
Wall Street Set to Open Lower After Red Hot Week; Fed Gov Warns Inflation Fight Not Over MT
US Futures Nudge Lower Premarket as Fed Governor Warns Inflation Fight Not Over MT
Top Premarket Gainers MT
Transcript : Indivior PLC, Opiant Pharmaceuticals, Inc. - M&A Call
Indivior buys Opiant creating "comprehensive" treatment platform AN
Opiant Pharmaceuticals to Be Acquired by Indivior MT
Chart Opiant Pharmaceuticals, Inc.
More charts
Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing medicines for addictions and drug overdose. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdose. Its lead development product include OPNT003. The Company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD), and Acute Cannabinoid Overdose (ACO). The Company also is focused on other treatment opportunities within the addiction and drug overdose field.
More about the company